Multiple Sclerosis (MS) is the number one indication treated by StemGenex Medical Group with adipose-derived mesenchymal stem cell therapy and was the first of five observational studies led by Principal Investigator, Dr. Andre Lallande. The five observational studies registered with the National Institutes of Health (NIH) for multiple sclerosis (MS), parkinson’s, rheumatoid arthritis, chronic obstructive pulmonary disease and osteoarthritis have been established to evaluate the quality of life changes in individuals following adipose-derived stem cell treatment.
Research on Multiple Sclerosis and stem cells shows that adipose-derived mesenchymal stem cell therapy may potentially repair the damage and inflammation seen in the nervous system of patients with MS. During an autoimmune reaction, the myelin sheath coating, which is formed around the axons of neurons, slowly deteriorates, thus causing physical and cognitive impairments. By calming down the autoimmune attack and attenuating inflammation, adipose-derived mesenchymal stem cell therapy may halt the progression, and potentially reverse the damage, of MS.
Numerous studies have demonstrated the potential of adipose-derived mesenchymal stem cells (MSCs) in treating the different types of MS. In Saudi Arabia, a group of researchers published the literature review, “The Immunomodulatory and Neuroprotective Effects of Mesenchymal Stem Cells (MSCs) in Experimental Autoimmune Encephalomyelitis (EAE): A Model of Multiple Sclerosis (MS),” describing how MSCs prevent progressive damage in mice induced with MS. The cells secrete soluble factors that inhibit the T-cells contributing to the autoimmune attack, thus protecting neurons from further damage.
In the study, “Mesenchymal Properties of SJL Mice-Stem Cells and Their Efficacy as Autologous Therapy in a Relapsing-Remitting Multiple Sclerosis Model,” researchers in Spain isolated MSCs from one mouse and transplanted the cells into another mouse with an experimental model of relapse-remitting multiple sclerosis. The mice receiving cells rather than saline as a control exhibited lower clinical scores and slower disease progression. These results were confirmed with another mouse strain, demonstrating the robustness of the promising MS treatment.
Additional evidence that corresponds with the work conducted by StemGenex Medical Group researchers comes from a group of researchers and clinicians from the United Kingdom who treated MS patients in the study, “Autologous Mesenchymal Stem Cells for the Treatment of Secondary Progressive Multiple Sclerosis: An Open-Label Phase 2a Proof-of-Concept Study.”
Research findings show that intravenous administration of autologous mesenchymal stem cells to patients with secondary progressive multiple sclerosis is feasible and safe and suggests structural, functional, and physiological improvement in patients after receiving treatment with autologous MSCs, which is consistent with remyelination. In addition, patients experienced enhanced visual acuity.
The observational study sponsored by StemGenex, “Outcomes Data of Adipose Stem Cells to Treat Multiple Sclerosis,” has been established to evaluate the quality of life changes measured by the Multiple Sclerosis Quality of Life Inventory (MSQLI) in individuals following mesenchymal adipose-derived stem cell therapy. Patients are brought to StemGenex Medical Group treatment center in California as part of a three-day treatment plan. The minimally invasive surgical procedure consists of cell isolation, activation, and re-administration, where the patient’s own stem cells are administered via full body IV and through additional customized administrations. By understanding the needs of each individual, each person receives a personalized health care plan by a board certified physician, tailored around that person’s indication and symptoms. StemGenex Medical Group is committed and focused on developing a post care Health Recovery Plan, which includes multiple treatment modalities and utilizes an integrative approach to achieve optimal long-term health.
Gretchen Sayword, a 54-year-old woman with MS, is highly satisfied with the treatment she received from StemGenex Medical Group. “I feel my body healing itself, which is improving my mental health, too,” said Gretchen, in a patient testimonial she gave to StemGenex Medical Group. Gretchen was diagnosed with a rare form of MS in 2013. For treatment, Gretchen’s doctors had her try Botox® injections, acupuncture, low-dose naltrexone and Rituxan® infusions every six months, and even Feldenkrais therapy to reduce pain and gain mobility. As she was losing hope in her fight against MS, Gretchen heard about stem cell therapy through members of a Facebook group. “I was a little nervous, but I was very hopeful. I had reached the point where I would try anything to feel better.” Gretchen went to California for treatment in July 2015. “The team is phenomenal. They all treated me so well and I really appreciated their follow up calls to check on me.” Whereas before, Gretchen was discouraged, after receiving treatment from StemGenex Medical Group, she is feeling less fatigued and more coordinated. “I would definitely encourage [another MS patient in my situation] to do it.”
Recently, the REGROW Act was introduced by U.S. Senators and House Representatives, bipartisan legislation to accelerate the development of stem cell therapies, which have the potential to fully restore or establish normal function in damaged human cells, tissues and organs for those living with diseases and untreatable conditions. “The development of regenerative medical treatments is one of the most exciting aspects of modern medicine,” said U.S. Representative Mike Coffman (R-Colorado), in a press release.
The REGROW Act contains legislation to establish a unique regulatory pathway tailored specifically for stem cell therapies, which can reduce both the time and cost of delivering safe and effective stem cell therapies to patients. “Groundbreaking new achievements in regenerative medicine therapies are reached every day, but they get stalled in the FDA approval process because the treatments are often too personal to scale up to large clinical trials,” said Mark Takai, in a press release. “Regenerative medicine is based on specific patient needs, using a patient’s own cells to grow healthy tissue to treat often fatal diseases. This bill cuts through the bureaucratic red tape.”
This issue is so important that the two Houses of Congress from both main political parties introduced the bills, S 2689 and HR 4762. “Bipartisan Policy Center commends Senators Mark Kirk (R-Illinois), Joe Manchin (D-West Virginia), Susan Collins (R-Maine) and Representatives Mike Coffman (R-Colorado), Mark Takai (D-Hawaii), and Morgan Griffith (R-Virginia) for their collaboration and introduction of the REGROW Act,” said Janet Marchibroda, in a press release.
Stem cell therapy is one of the most exciting aspects of modern medicine and StemGenex Medical Group is committed to helping people suffering from diseases and untreatable conditions. With time, adipose-derived mesenchymal stem cell therapy may potentially replace the standard of care given to patients today.
If you or someone you know is interested in learning more about stem cell treatment, call (855) 742-STEM to speak with a StemGenex Medical Group Patient Advocate.
This testimonial includes a description of this patient’s actual results. These results may not be typical or expected for the particular disease type described in this testimonial. You should not expect to experience these results. Stem cell therapy is not FDA approved and is not a cure for any medical condition.